Gustav Hedström
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gustav Hedström has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Gunilla Enblad
Department of Radiology, Oncology and Radiation Sciences Section of Oncology Uppsala University Uppsala Sweden
3 shared publicationsMattias Berglund
Department of Radiology, Oncology and Radiation Sciences Section of Oncology Uppsala University Uppsala Sweden
3 shared publicationsUlf Thunberg
Department of Radiology, Oncology and Radiation Sciences Section of Oncology Uppsala University Uppsala Sweden
3 shared publicationsRose‐Marie Amini
Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden
2 shared publicationsChrister Sundström
Department of Genetics and Pathology, Uppsala University
1 shared publicationDaniel Molin
Department of Oncology, Radiology and Clincial Immunology, Uppsala University, Uppsala
1 shared publication
Latest Publications
- 21 June 2014
- Published by Wiley in European Journal of Haematology
- Vol. 93 (6) , 500-508
The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B‐cell lymphoma
Introduction: The murine double minute 2 (MDM2) gene encodes a regulatory protein of the p53 pathway. A single nucleotide polymorphism (T to G change) at position 309 (SNP309) in the promotor region of MDM2 affects the transcription activity of MDM2 and has been found to be a negative prognostic marker in several cancers.Patients and methods: In this study, the MDM2 SNP309 polymorphism was analysed in 201 patients with diffuse large B‐cell lymphoma and analysed in relation to clinical characteristics and prognosis.Results: Patients homozygous for SNP309T had a significantly longer overall survival, lymphoma‐specific survival and disease‐free survival (P = 0.002; 0.004 and 0.006 respectively) compared to patients carrying a G allele. The longer overall survival was seen in the subgroup of patients not treated with Rituximab, however, not for Rituximab‐treated patients (P = 0.01 and 0.2 respectively). The group homozygous for the T allele also had lower age at diagnosis, a tendency towards lower aaIPI and a significantly lower proportion of patients with p53 aberrations compared to the group including at least one G allele. However, the survival differences persisted even after removal of cases with known p53 aberrations from the analysis.Conclusion: Polymorphism in MDM2 SNP309 could be correlated to some clinical characteristics and for patients not treated with immunotherapy, a G allele was correlated to poor survival, whereas no survival differences were found for patients treated with Rituximab. Herewith, we provide additional information about Diffuse large B‐cell Lymphoma (DLBCL) biology and highlight the importance of evaluation of molecular markers in relation to treatment.
- 21 June 2014
- Published by Wiley in European Journal of Haematology
- Vol. 93 (6) , 500-508
The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B‐cell lymphoma
Introduction: The murine double minute 2 (MDM2) gene encodes a regulatory protein of the p53 pathway. A single nucleotide polymorphism (T to G change) at position 309 (SNP309) in the promotor region of MDM2 affects the transcription activity of MDM2 and has been found to be a negative prognostic marker in several cancers.Patients and methods: In this study, the MDM2 SNP309 polymorphism was analysed in 201 patients with diffuse large B‐cell lymphoma and analysed in relation to clinical characteristics and prognosis.Results: Patients homozygous for SNP309T had a significantly longer overall survival, lymphoma‐specific survival and disease‐free survival (P = 0.002; 0.004 and 0.006 respectively) compared to patients carrying a G allele. The longer overall survival was seen in the subgroup of patients not treated with Rituximab, however, not for Rituximab‐treated patients (P = 0.01 and 0.2 respectively). The group homozygous for the T allele also had lower age at diagnosis, a tendency towards lower aaIPI and a significantly lower proportion of patients with p53 aberrations compared to the group including at least one G allele. However, the survival differences persisted even after removal of cases with known p53 aberrations from the analysis.Conclusion: Polymorphism in MDM2 SNP309 could be correlated to some clinical characteristics and for patients not treated with immunotherapy, a G allele was correlated to poor survival, whereas no survival differences were found for patients treated with Rituximab. Herewith, we provide additional information about Diffuse large B‐cell Lymphoma (DLBCL) biology and highlight the importance of evaluation of molecular markers in relation to treatment.
- 5 March 2013
- Published by Springer Nature in International Journal of Hematology
- Vol. 97 (4) , 465-471
Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of B cell lymphomas. MicroRNA expression provides a new and interesting tool for understanding the biology and clinical course of DLBCL. The present study presents microRNA-129-5p expression data from DLBCL patients treated with CHOP or R-CHOP. Patients with low microRNA-129-5p expression had a median survival of 23 months and a significantly shorter overall survival (P = 0.0042) compared to patients with high microRNA-129-5p expression, who had a median survival of 58 months. We also found that patients treated with R-CHOP only and displaying low microRNA-129-5p expression had a significantly shorter overall survival compared to patients with high microRNA-129-5p expression; all such patients were still alive at the time of last follow-up (P = 0.043). No significant difference was found among microRNA-129-5p expression in tumor tissue, the tissue surrounding the tumor, and normal controls. To our knowledge, this is the first report to show that the expression of microRNA-129-5p can affect the clinical outcome of DLBCL patients and that microRNA-129-5p may be involved in the biology of DLBCL development, although larger studies are necessary to confirm this. Further investigations may also help to elucidate the biological role of microRNA-129-5p in DLBCL.
- 5 March 2013
- Published by Springer Nature in International Journal of Hematology
- Vol. 97 (4) , 465-471
Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of B cell lymphomas. MicroRNA expression provides a new and interesting tool for understanding the biology and clinical course of DLBCL. The present study presents microRNA-129-5p expression data from DLBCL patients treated with CHOP or R-CHOP. Patients with low microRNA-129-5p expression had a median survival of 23 months and a significantly shorter overall survival (P = 0.0042) compared to patients with high microRNA-129-5p expression, who had a median survival of 58 months. We also found that patients treated with R-CHOP only and displaying low microRNA-129-5p expression had a significantly shorter overall survival compared to patients with high microRNA-129-5p expression; all such patients were still alive at the time of last follow-up (P = 0.043). No significant difference was found among microRNA-129-5p expression in tumor tissue, the tissue surrounding the tumor, and normal controls. To our knowledge, this is the first report to show that the expression of microRNA-129-5p can affect the clinical outcome of DLBCL patients and that microRNA-129-5p may be involved in the biology of DLBCL development, although larger studies are necessary to confirm this. Further investigations may also help to elucidate the biological role of microRNA-129-5p in DLBCL.
- Open Access
- 6 June 2007
- Published by Wiley in British Journal of Haematology
- Vol. 138 (1) , 68-71
Mast cell infiltration is a favourable prognostic factor in diffuse large B‐cell lymphoma
Previous studies indicate that the inflammatory response in diffuse large B‐cell lymphomas (DLBCL) is important for the clinical outcome. Mast cells are key regulators in this response; we investigated whether the number of tryptase‐positive mast cells is correlated with clinical outcome. Patients with many mast cells had a significantly better event‐free survival (EFS) compared to those with few mast cells (P < 0·03 in both germinal centre (GC) and non‐GC DLBCL. This supports the idea that the infiltration of mast cells is a reflection of the host inflammatory response and is related to a favourable outcome.
- 6 June 2007
- Published by Wiley in British Journal of Haematology
- Vol. 138 (1) , 68-71
Open AccessMast cell infiltration is a favourable prognostic factor in diffuse large B‐cell lymphoma
Previous studies indicate that the inflammatory response in diffuse large B‐cell lymphomas (DLBCL) is important for the clinical outcome. Mast cells are key regulators in this response; we investigated whether the number of tryptase‐positive mast cells is correlated with clinical outcome. Patients with many mast cells had a significantly better event‐free survival (EFS) compared to those with few mast cells (P < 0·03 in both germinal centre (GC) and non‐GC DLBCL. This supports the idea that the infiltration of mast cells is a reflection of the host inflammatory response and is related to a favourable outcome.